Minerva Neurosciences tanks (NERV -81.4%) after the company announces disappointing results from Phase 3 clinical trial evaluating roluperidone …
Link to Full Article: Read Here
May 29, 2020 | News Stories
Minerva Neurosciences tanks (NERV -81.4%) after the company announces disappointing results from Phase 3 clinical trial evaluating roluperidone …
Link to Full Article: Read Here